Cutaneous Lupus Erythematosus Clinical Trials

A listing of Cutaneous Lupus Erythematosus medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

UPDATED

Contact LILAC Research Site Directly
Anniston Alabama 36207

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Anniston Alabama 36207

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Anniston Alabama 36207

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Arizona

UPDATED

Contact LILAC Research Site Directly
Phoenix Arizona 85037

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

View More ▼

Phoenix Arizona 85032

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

California

UPDATED

Contact LILAC Research Site Directly
La Mesa California 91942

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
La Mesa California 91942

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Los Angeles California 90045

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Los Angeles California 90045

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Tustin California 92780

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Tustin California 92780

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Upland California 91786

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

UPDATED

Contact LILAC Research Site Directly
Upland California 91786

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Upland California 91786

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Research Center
Upland California 91786

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Di
West Hills California 91307

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
West Hills California 91307

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Los Angeles California 90045

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

San Diego California 92120

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Tustin California 92780

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Upland California 91786

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

West Hills California 91307

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

West Hollywood California 90048

Patients are needed to participate in a clinical research study of Milatuzumab

Florida

Orlando Florida 32806

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Georgia

UPDATED

Contact LILAC Research Site Directly
Sandy Springs Georgia 30328

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Sandy Springs Georgia 30328

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Atlanta Georgia 30342

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Indiana

Research Center
Indianapolis Indiana 46256

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Indianapollis Indiana 46256

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

View More ▼

Indianapolis Indiana 46256

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Massachusetts

UPDATED

Contact LILAC Research Site Directly
Boston Massachusetts 02115

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Boston Massachusetts 02115

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Missouri

UPDATED

Contact LILAC Research Site Directly
St. Louis Missouri 63110

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
St. Louis Missouri 63110

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Nevada

UPDATED

Contact LILAC Research Site Directly
Las Vegas Nevada 89128

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

NEW

Research Center
Las Vegas Nevada 89128

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

New Jersey

UPDATED

Contact LILAC Research Site Directly
Summit New Jersey 07901

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

UPDATED

Contact LILAC Research Site Directly
Summit New Jersey 07901

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

View More ▼

Summit New Jersey 07901

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

New York

UPDATED

Contact LILAC Research Site Directly
Great Neck New York 11021

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Great Neck New York 11021

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Great Neck New York 11020

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

North Carolina

UPDATED

Contact LILAC Research Site Directly
Charlotte North Carolina 28207

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

UPDATED

Contact LILAC Research Site Directly
Charlotte North Carolina 28204

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Charlotte North Carolina 28207

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Research Center
Charlotte North Carolina 28204

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Research Center
Wilmington North Carolina 28401

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Charlotte North Carolina 28207

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Charlotte North Carolina 28204

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)